主页
市场
图表与思路
Algo
新闻
商店
经纪商
下载
经济日历
交易信号
网页端
热图
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
IMCR
#4436
Immunocore Holdings plc - American Depositary Shares
0.2
9
USD
-99.00%
版块:
医疗保健
基础:
USD
利润货币:
USD
日范围
年范围
日变化
-99.00%
每月变动
-98.97%
6个月变化
-99.26%
年变化
-99.14%
前一天收盘价
28.9
7
Open
0.2
9
最低价
0.2
9
High
0.2
9
交易量
29
市场
US Stock Market
医疗保健
IMCR
展开完整图表
完整图表
Financials
概览
声明
统计
每季度
年度
值
2020
2021
2022
2023
2024
2025
当前
Key stats
已发行普通股总额
31.78 M
43.86 M
48.09 M
49.82 M
50.07 M
50.7 M
50.87 M
Valuation ratios
企业价值
—
1.5 B
2.67 B
3.17 B
1.41 B
1.69 B
1.39 B
市盈率
—
—
—
-63.4
-28.92
-48.89
-50.89
市销率
—
—
—
14.04
4.75
4.37
3.52
市现率
—
—
—
1 191.29
56.59
-163.13
-59.25
市净率
—
—
—
9.5
4.09
4.59
0.93
企业价值与息税折旧摊销前利润比率
—
—
—
-57.15
-21.31
-39.88
-44.72
Profitability ratios
资产回报率 %
—
—
—
-0.09
-0.05
-0.03
0.01
股本回报率 %
—
—
—
-0.15
-0.14
-0.09
0.03
投入资本回报率 %
—
—
—
-126.09
-131.84
-126.65
10.73
毛利率 %
—
—
—
99.58
99.12
98.73
99.59
营业利润率 %
—
—
—
-23.91
-22.71
-11.34
6.82
息税折旧摊销前利润率 %
—
—
—
-22.27
-21.36
-10.56
7.71
净利润率 %
—
—
—
-22.17
-16.47
-8.88
12.16
Liquidity ratios
速动比率
—
—
—
3.77
4.36
4.01
4.15
流动比率
—
—
—
3.8
4.38
4.04
4.18
库存周转率
—
—
—
—
—
—
—
资产周转率
—
—
—
0.42
0.39
0.37
0.1
Solvency ratios
负债资产比
—
—
—
0.08
0.39
0.37
0.37
负债权益比
—
—
—
0.13
1.08
1.03
1
长期负债与总资产比率
—
—
—
0.17
0.39
0.37
0.37
长期负债与总权益比率
—
—
—
0.27
1.08
1.03
1
Per share metrics
每股经营现金流量
—
—
—
0.06
0.52
-0.21
-0.48
每股息税前利润
—
—
—
-1.22
-1.41
-0.9
-0.69
每股息税折旧及摊销前利润
—
—
—
-1.14
-1.33
-0.84
-0.63
每股总负债
—
—
—
0.98
7.82
7.81
7.44
每股现金
—
—
—
9.05
16.41
17.16
15.96
每股净资产
—
—
—
10.82
18.6
19.8
18.96
每股有形账面价值
—
—
—
7.54
7.22
7.57
7.44
每股营运资本
—
—
—
7.97
14.36
14.9
14.43
每股账面价值
—
—
—
7.54
7.22
7.57
7.44
Immunocore Holdings plc - American Depositary Shares
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.
新闻
FDA Grants Priority Review to SNY's Filing for Gaucher Disease Drug
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study
CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up
AbbVie Wins FDA Nod for Decnupaz for Rare Blood Cancer Indication
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy
FDA Extends Review Time for AZN's Camizestrant Combo in Breast Cancer
Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now?
AZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid Tumors
AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast Cancer
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe
GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy
CHMP Backs EU Approval of Novo Nordisk's Wegovy Pill for Obesity